Table 1.
Clinical data of the enrolled patients
| PN group | PUFA group | |
| Sex (M/F) | 23/10 | 22/11 |
| Age, yr | 48.62 ± 14.61 | 51.52 ± 12.41 |
| Clinical diagnosis | ||
| Hepatic cell carcinoma | 13 | 14 |
| Post- hepatitis B liver cirrhosis | 17 | 18 |
| Alcoholic liver cirrhosis | 1 | 0 |
| Primary biliary liver cirrhosis | 1 | 1 |
| Congenital polycystic liver | 1 | 0 |
| Child-Pugh classification (A/B/C) | 14/10/9 | 13/10/10 |
| Warm ischemic time (min) | 3.91 ± 1.16 | 4.15 ± 1.32 |
| Cold ischemic time (min) | 524.28 ± 132.83 | 506.56 ± 151.26 |
| Operation period (min) | 651.27 ± 181.42 | 626.39 ± 192.86 |
| Anhepatic phase (min) | 119.81 ± 82.35 | 142.15 ± 58.75 |
| Immunosuppressive therapy | 22/11/0 | 21/11/1 |
| (FK506 + P/CSA + P/CSA + P + MMF) |
PN: Parenteral nutrition; PUFA: Polyunsaturated fatty acid; P: Prednisone; CSA: Ciclosporin A; MMF: Mycophenolate mofetil; FK506: Tacrolimus.